Northland Securities Reaffirms Their Buy Rating on Viewray (VRAY)

In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on Viewray (VRAYResearch Report), with a price target of $20. The company’s shares opened today at $8.68.

According to, Kalia is a 5-star analyst with an average return of 11.0% and a 60.0% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Strata Skin Sciences Inc.

Currently, the analyst consensus on Viewray is a Strong Buy with an average price target of $13.67.

See today’s analyst top recommended stocks >>

The company has a one-year high of $13.21 and a one-year low of $4.86. Currently, Viewray has an average volume of 882.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ViewRay, Inc. engages in the design, manufacture and market magnetic resonance imaging (MRI) system. It develops MRIdian to address the key limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.